Cargando…

Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides

OBJECTIVE: The objective of this study was to evaluate the long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients at goal for low-density lipoprotein cholesterol (LDL-C) but with persistent hypertriglyceridemia. METHODS: This is a post hoc analysis of a subset of pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ballantyne, Christie M., Jones, Peter H., Kelly, Maureen T., Setze, Carolyn M., Lele, Aditya, Thakker, Kamlesh M., Stolzenbach, James C.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer US 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070075/ https://www.ncbi.nlm.nih.gov/pubmed/21416219 http://dx.doi.org/10.1007/s10557-011-6280-1

Ejemplares similares

The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia
por: Bays, Harold E., et al.
Publicado: (2010)

Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial
por: Davidson, Michael, et al.
Publicado: (2012)

Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus
por: Rosenson, Robert S., et al.
Publicado: (2010)

Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis
por: Brinton, Eliot A., et al.
Publicado: (2018)

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
por: Brinton, Eliot A, et al.
Publicado: (2013)

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study
por: Ballantyne, Christie M., et al.
Publicado: (2019)

Assessment of fenofibrate-methylation interactions on triglycerides using longitudinal family data
por: Yu, Jih-Chang, et al.
Publicado: (2018)

Investigation of parent-of-origin effects induced by fenofibrate treatment on triglycerides levels
por: Sarnowski, Chloé, et al.
Publicado: (2018)

Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins
por: Leatherman, Sarah, et al.
Publicado: (2022)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Statin-Induced Diabetes: Will It Change Clinical Practice?
por: Belalcazar, L. Maria, et al.
Publicado: (2009)

Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin-Treated Subjects From 3 Data Sources: A Retrospective Analysis
por: Jones, Peter H., et al.
Publicado: (2012)

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial
por: Rodriguez-Gutierrez, Rene, et al.
Publicado: (2022)

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
por: Moutzouri, Elisavet, et al.
Publicado: (2010)

A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
por: Filippatos, Theodosios D.
Publicado: (2012)

Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction
por: Woo, Yeongmin, et al.
Publicado: (2018)

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
por: Alagona, Peter
Publicado: (2010)

Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study
por: Kim, Nam Hoon, et al.
Publicado: (2019)

The PPAR Alpha gene is associated with triglyceride, low-density cholesterol, and inflammation marker response to fenofibrate intervention: The GOLDN Study
por: Frazier-Wood, A.C., et al.
Publicado: (2012)

Modification effect of fenofibrate therapy, a longitudinal epigenomic-wide methylation study of triglycerides levels in the GOLDN study
por: Wei, Runmin, et al.
Publicado: (2018)

A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
por: Ling, Hua, et al.
Publicado: (2013)

Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
por: Budoff, Matthew J, et al.
Publicado: (2020)

Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin‐Associated Side Effects
por: Ahmed, Sarah T., et al.
Publicado: (2020)

The Combination Therapy of Fenofibrate and Ezetimibe Improved Lipid Profile and Vascular Function Compared with Statins in Patients with Type 2 Diabetes
por: Shinnakasu, Atsushi, et al.
Publicado: (2017)

Detecting responses to treatment with fenofibrate in pedigrees
por: Cherlin, Svetlana, et al.
Publicado: (2018)

A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy
por: Strain, Joe D, et al.
Publicado: (2010)

Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series
por: Castaldo, Richard S.
Publicado: (2016)

Persistence with statin therapy in Hungary
por: Kiss, Zoltan, et al.
Publicado: (2013)

Fibrane the reduced derivative of fenofibrate
por: Kotheimer, Amanda E., et al.
Publicado: (2019)

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
por: Patel, Piyush, et al.
Publicado: (2016)

Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy
por: Wiggin, Timothy D., et al.
Publicado: (2009)

Exceptionally elevated triglyceride in severe lipemia retinalis
por: Yin, Han Y, et al.
Publicado: (2016)

Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential()()
por: Stalinska, J., et al.
Publicado: (2019)

Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner
por: Theusch, E, et al.
Publicado: (2017)

Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study
por: Liberopoulos, E.N, et al.
Publicado: (2010)

Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
por: Davis, Timothy M.E.
Publicado: (2020)

Rosiglitazone and Fenofibrate Additive Effects on Lipids
por: Slim, Ahmad, et al.
Publicado: (2011)

Effect of Fenofibrate Medication on Renal Function
por: Kim, Sungjong, et al.
Publicado: (2017)

Fenofibrate-induced renal dysfunction, yes or no?
por: Emami, Fatemeh, et al.
Publicado: (2020)

The role of fenofibrate in the treatment of COVID-19
por: Yasmin, Farah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rmprmc1ads48afi7q873ejeou9